J
Jiangsu Care Medical Technology
Hollow fiber membranes for blood purification biopharmaceuticals
About Jiangsu Care Medical Technology
Jiangsu Solicitude Medical Technology Co., Ltd. (SMT Group), founded in 2019, is a high-tech enterprise based in Suzhou, Jiangsu Province, specializing in membrane science products for the biopharmaceutical and blood purification industries. The company's business model encompasses the entire product lifecycle, including research and development, manufacturing of equipment and assembly lines, and production of finished goods. It serves clients in the biopharmaceutical and blood purification sectors by providing customizable medical hollow fiber membranes and filters.
SMT Group's core product offerings are centered around medical hollow fiber membranes. Its product portfolio includes a range of filters such as hemodialyzers, dialysate filters, and water filters for dialysis, alongside tangential flow filtration (TFF) hollow fiber columns and flat membrane cassettes. The company has the manufacturing capacity to produce 12 million bundles of hollow fiber membranes and 10 million hollow fiber dialyzers annually. SMT Group's facilities operate as 100,000-level clean workshops and have obtained ISO 13485 certification and EU CE product certification, ensuring compliance with GMP standards.
The company focuses on high-growth medical markets, including gene therapy, vaccine production, and the established blood dialysis market. In July 2022, its ZOE® series hemodialyzer received NMPA approval and was launched in the Chinese domestic market. SMT Group's strategic objective is to advance the localization of blood purification medical devices and support the development of the biopharmaceutical industry in China.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2023 | $14M | $138M | Shunbai Capital · Neovision Capital · CCB Trust | ↗ |
| SERIES COther financing | Jun 2023 | $28M | $110M | China Life Private Equity Investment · Shanghai CICC Capital | ↗ |
Growth signals
Latest recorded traffic for Jiangsu Care Medical Technology is 370 monthly website visits, up 32.1% over the last three months. Jiangsu Care Medical Technology's team grew 10.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiangsu Care Medical Technology in the Jiuquan ecosystem
The Jiangsu Care Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
River Head Capital- SMShenzhen Cornerstone Asset Management
- SISuzhou Wuzhong Biomedicine Industrial Park Investment
- HIHongrui Investment
Sherpa Venture Partners
BioTrack Capital
Series B and later5 investors entered at this stage
- CIChina Life Private Equity Investment
Shanghai CICC Capital- SCShunbai Capital
- NCNeovision Capital
- CTCCB Trust
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiangsu Care Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiangsu Care Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








